Day 1

• Subcutaneous RYBREVANT data soaring high with unexpectedly better performance than its Intravenous version

• Post failure of Gilead’s Trodelvy in confirmatory bladder cancer trial, the ADC  has bad news in NSCLC, although it shows survival benefits to non-responders to PD-(L)1 blockade

• With the planned submission of SCEMBLIX in 2024 for 1L CML, the Phase III ASC4FIRST trial meets both primary endpoints with clinically meaningful and statistically significant results

• Summit’s lead bispecific (PD-1 X VEGF) data beats Merck’s Keytruda. Company Stocks jump after HARMONi-A trial findings released for EGFR-mutant non-squamous non-small cell lung cancer

• Johnson & Johnson broadening RYBREVANT’s label, now moving towards EGFR exon 19 deletions or L858R mutations in first-line NSCLC

• Merck and Kelun’s new TROP-2 ADC, Sacituzumab Tirumotecan (SKB264/MK-2870) shines in advanced NSCLC in Phase II trial

• Non-squamous histology in NSCLC, appears to derive the greatest benefit with Dato-DXd, data from the ICARUS-LUNG01 study revealed

• China-based Curon Biopharma’s bispecific CN201, a Next Generation CD3 × CD19 T-cell Engager, reports the longest duration of response of 8 months in R/R B-cell ALL patients

• Post KYMRIAH and YESCARTA, Autolus’ CD-19 CAR-T, Obe-cel is expected to receive approval in R/R B-cell ALL patients

• Novartis planning to strengthen its portfolio with Pelabresib and JAKAFI Combo, a Breakthrough in reducing Splenomegaly for JAK Inhibitor naive Patients

Day 2

• Fulzerasib emerges as a game-changer for KRAS G12C-mutated NSCLC with promising preliminary efficacy and an excellent safety profile in Phase II KROCUS Study!

• Adagrasib shines in KRYSTAL-12 trial in confirmatory trial:  Will the FDA be convinced despite Progression-Free Survival Debate?

• Lilly’s Verzenio is expected to be a promising option in HR+, HER2- advanced breast cancer patients after disease progression on a CDK4/6 inhibitor, regardless of biomarker status

• Sigvotatug Vedotin, Pfizer's Most Anticipated Antibody Drug Conjugate (ADC) in NSCLC Treatment - Updated Phase I Insights Unveiled

• Data from Pivotal Phase II TRUST-I study of taletrectinib, a ROS1 inhibitor: One of the largest trials to date among people with ROS1-positive NSCLC!

• Sunvozertinib: Shanghai-based biopharmaceutical company, Dizal Paving the Global Path for EGFR Exon 20 Insertion Mutation Treatment

• The addition of CDK4/6 inhibitor, VERZENIO to ZYTIGA did not significantly improve rPFS in mCRPC patients, Lilly presents data from CYCLONE 2 trial

• Cantargia's Nadunolimab, dual Benefits in Pancreatic Ductal Adenocarcinoma (PDAC) Treatment - Antitumor Efficacy and Neuropathy Reduction – CANFOUR Study

• FutureGen’s CLDN18.2 inhibitor, FG-M108 Achieves 100% Disease Control in Advanced Pancreatic Cancer

• Merck’s First-in-Class ILT3 Targeted Therapy Shows Promising Phase I Results in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

• Alligator Bioscience’s CD40 inhibitor, Mitazalimab Shows Promising Results in OPTIMIZE-1 Trial for Pancreatic Cancer, Paving the Way for Phase III Development

• ENHERTU Gains Momentum due to Tumor Agnostic Label in HER2+ solid Tumors. How well are the outcomes in Biliary Tract and Pancreatic Cancer patients?

• Compugen presents encouraging preliminary results from COM701, a triple combination in microsatellite stable colorectal cancer with liver metastases

• PolyPEPI1018, an off-the-shelf peptide immunotherapy by Treos Bio, was well-tolerated in its Phase II study of late-stage microsatellite stable metastatic colorectal cancer patients

• Promising efficacy of Innovent Biologics’ PD-1/IL-2 bispecific antibody fusion protein, IBI363 observed in advanced CRC patients, particularly in PD-L1 CPS ≥1

• Agenus’ Botensilimab/Balstilimab combo breakthrough data is out for relapsed/refractory metastatic colorectal cancer (mCRC) patients

• Cue Biopharma’s T-cell engager CUE-102 shows favorable data in HLA-A*0201-positive disease and WT1-positive recurrent/metastatic cancers

• Post blockbuster IBRANCE’s success, Pfizer is now having hopes for its next-generation CDK4-selective inhibitor, in HR+ HER2- breast cancer patients

• Encouraging activity in heavily pretreated patients with advanced colorectal cancer by Merck’s first-in-class anti-CEACAM5 ADC with topoisomerase 1 inhibitor payload, M9140

• Post Enhertu’s recent achievement after gaining a tumor agnostic label in previously treated HER2+ solid tumors, the HER2-ADC is now moving upwards for first-line HER2+ metastatic breast cancer

• Pfizer and Astellas’ Nectin-4 ADC, Padcev being evaluated in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer cohorts of the EV-202 trial

• Exciting news for Roche’s PIKCA-mutated, Inavolisib in  HR+HER2 metastatic Breast Cancer patients as it yields better results than Novartis’ PIQRAY

Day 3

• Mainz Biomed unveils consolidated findings from both ColoFuture and eAArly DETECT study. 92% sensitivity for Colorectal Cancer seems remarkable

• Natera’s latest results from the CIRCULATE-Japan GALAXY study, showcasing the prognostic and predictive value of Signatera and actionable biomarkers in colorectal cancer

• LabCorp's validation study of Labcorp Plasma Complete test provides highly specific and accurate detection in advanced stage cancers

• Precede Biosciences' assay determines HER2 status in multiple cancer types with HER2 protein as a hallmark biomarker

• Interim data readout from Guardant’s RADIOHEAD study, to identify genomic and epigenomic biomarkers using Guardant Infinity in more than 13 cancer types

• GRAIL’s Multi Cancer Early Detection test (MCED) detects aggressive cancers with high specificity, whereas early-stage cancer can get skipped in the PATHFINDER study

• HER2 low breast cancer seems to be an evolving space. Eisai presented the most recent findings on BB-1701's anti-HER2 activity in low HER2 expressing breast cancer type

• Blueprint’s BLU-222, a promising CDK2 inhibitor, demonstrates potential in HR+/HER2- breast cancer

• Merck & Kelun’s TROP-2 ADC could be a ray of hope post Phase III data readout highlighting its efficacy in the most aggressive breast cancer type, TNBC

Day 4

• Bayer’s BAY2927088 demonstrates exceptional performance as a novel TKI for HER2-Mutant NSCLC

• Exact Sciences evaluated the potential impact of MCED screening on Stage IV cancer incidence for 12 cancers that represent 70% of all cancer incidence in the US

• A saliva-based test that could transform the way prostate cancer is diagnosed, findings from BARCODE 1 study

• Shanghai's latest Phase Ib/II results reveal promising objective response rate and a well-managed safety profile in Extensive Stage-Small Cell Lung Cancer (ES-SCLC) patients

• While major players emphasize MRD detection in Advanced cancers, Foresight Diagnostics focuses on early-stage NSCLC patients within the post-operative adjuvant setting

• FDA Lifts partial hold on Innate Pharma’s lacutamab program, reveals positive clinical activity for mycosis fungoides regardless of KIR3DL2 expression

• Seagen’s ADCETRIS might be a promising treatment for PTCL patients with less than 10% CD30 expression

• Chinese player evaluating PI3Kα/δ inhibitor, TQ-B3525 in heavily pretreated relapsed/refractory follicular lymphoma

• Caribou Biosciences’ Allogeneic CAR-T Therapy, CB-010, demonstrates promising results in relapsed/refractory B-NHL (r/r B-NHL) patients

• Merus' Petosemtamab is emerging as a potential best-in-class option for first-line HNSCC treatment

• Mercy BioAnalytics highlighted the performance of its Mercy Halo Ovarian Cancer screening test in a large cohort of asymptomatic, postmenopausal women

• Exciting Breakthrough for Arvinas’ Novel PROTAC Androgen Receptor, ARV-766, expected to be the first of its kind in metastatic castration-resistant prostate cancer (mCRPC)

• Spanish player, Amadix presented performance data of PreveCol test for colorectal cancer screening

• BillionToOne’s already launched assay, Northstar Select has come out favorably in a head-to-head comparison with commercially available assays

• Adela’s tissue-agnostic MRD assay’s performance for recurrence prediction in patients with head and neck cancer. All set to commercialize the test for clinical use in 2025

• Personalis NeXT Personal test has shown exceptional ability in identifying molecular residual disease and predicting relapse in early-stage breast cancer